PTC Therapeutics Inc. is a PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics.
PTC Therapeutics Inc. (PTCT) had a good day on the market for Tuesday January 12 as shares jumped 1.18% to close at $67.05. About 312,948 shares traded hands on 5,025 trades for the day, compared with an average daily volume of n/a shares out of a total float of 68.24 million. After opening the trading day at $66.33, shares of PTC Therapeutics Inc. stayed within a range of $68.52 to $66.33.
With today’s gains, PTC Therapeutics Inc. now has a market cap of $4.58 billion. Shares of PTC Therapeutics Inc. have been trading within a range of $70.82 and $30.80 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
PTC Therapeutics Inc. is based out of South Plainfield, NJ and has some 761 employees. Its CEO is Stuart W. Peltz.